focus -WSS

focus

author：knowledge 2025-09-28 01:36:42 - browse：5

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： 23andMe had bad news about my health. I wish a person had delivered it

focus

WSS

Vaccine advisory panel ACIP left half staffed by HHS

Private equity deals in Medicare Advantage declines

Biden report: The neurospychology of memory and aging

Virginia high school admissions case could be legal follow

In age of alternative facts, a scholarly course on calling out crap

ChatGPT in medicine: STAT answers readers' burning questions

knowledge

focus

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

New air purifier tech could be key to improving indoor air quality

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Biogen Alzheimer’s drug launch off to slow start

Drug repurposing or repositioning? The language matters

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hepatitis C has a cure — but many Americans still lack access to it

Virginia high school admissions case could be legal follow

How to save PrEP access — and even expand it

hotspot

The dental labor crisis is a moment of opportunity

PhRMA lawsuit over Medicare drug price negotiation tossed

For Medicare Advantage, Democrats want stronger protections around AI

Key House Republican on health care plans exit from Congress

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Heart attack and stroke risk calculators need revising

explore

focus

hotspot

Wikipedia